Genmab — Maj 2023

[Klarussen]

NBI index -2,36% aktuelt. Ser ud som pengene flyttes over i tech,

[Pensionisten]

Genmab ADS -0,26%

[Klarussen]

Følger jo blot den danske kurs så nogenlunde, men man kan da håbe det holder

[peter12]

Abstracts https://ir.genmab.com/news-releases/news-release-details/genmab-announces-multiple-abstracts-be-presented-american

[ProinvestorNEWS]

Genmabs amerikanske notering får hævet kursmålet over 14 pct. af investeringsbank https://www.proinvestor.com/investornyt/991906/genmabs-amerikanske-notering-far-haevet-kursmalet-over-14-pct-af-investeringsbank

[Riis7]

Test af 2800 når usa åbner

[gdn55]

Sikkert, det er åbentbart negativt at få en ny medicin godkendt. Indtil videre i denne uge har vi kun tabt 12-13kr på denne godkendelse

[Klarussen]

Kortsigtede investorer smider vel medico i jagten på hurtige penge i AI mv. Held og lykke til dem, håber ikke de brænder nallerne...

[AaBforever]

Go´pinse til alle....trods noget skvulp i Genmab aktien:-)

[gdn55]

OK, det blev kun til et tab på 2 kr. på godkendelsen for en uge siden.

[E_L]

epcoritamab data in FL is wild, hope they can file this soon... Primary refractory ORR
97% CMR
87%

• Epcoritamab + R2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status. https://meetings.asco.org/abstracts-presentations/218265

[E_L]

Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data. https://meetings.asco.org/abstracts-presentations/218272 -Seems odd that double-hit/triple-hit lymphoma is doing as well as other patients in the trial?

[E_L]

Advanced cervical cancer therapy: Comparison of contemporary expert and healthcare professional recommendations from an online treatment decision tool. https://meetings.asco.org/abstracts-presentations/226499 In 2L recurrent disease, all experts chose either single-agent immunotherapy (if PD-L1 positive) or tisotumab vedotin (if PD-L1 negative) vs 45% and 40% of HCPs, respectively

[Darvin]

thanks E L - sounds fantastic, or rather fantastic. Epco's future looks somewhat better than the market expects so far. .

[E_L]

I think so too. But it will be hard keeping up with all the trials and cohorts and different subsets etc they are planning lol...

[E_L]

and i didn't check the abstracts for Dara , Talquetamab , teclistamab and amivantamab yet...

[gentogen]

Thanks EL. This really is KYSO!

[Stroka]

Thanks E L.

[E_L]

I think you should thank Genmab, not me lol

[paundal]

E L. You deserve a thank you. Thank you for your posts, which are always relevant and qualified. You always keeping your eyes on the ball!